296 related articles for article (PubMed ID: 38082244)
21. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.
Li X; Raventós B; Roel E; Pistillo A; Martinez-Hernandez E; Delmestri A; Reyes C; Strauss V; Prieto-Alhambra D; Burn E; Duarte-Salles T
BMJ; 2022 Mar; 376():e068373. PubMed ID: 35296468
[TBL] [Abstract][Full Text] [Related]
22. Vaccination in pediatric acquired inflammatory immune-mediated neuromuscular disorders.
Barišić N; Turudić D; Marić LS; Tešović G
Eur J Paediatr Neurol; 2022 Jan; 36():159-176. PubMed ID: 34998097
[TBL] [Abstract][Full Text] [Related]
23. Guillain-Barré Syndrome and COVID-19 Vaccine: A Multicenter Retrospective Study of 46 Cases.
Castiglione JI; Crespo JM; Bendersky M; Silveira FO; Lecchini L; Luis MB; Zambrano FC; Cotti N; Simison CJ; Aguirre F; Piedrabuena MA; Alonso RN; Azcona CL; Sosa PS; Maldonado E; Varela F; Bettini M; Rey RD; Cejas LL; Rugiero M; Reisin R; Barroso F
J Clin Neuromuscul Dis; 2023 Sep; 25(1):1-10. PubMed ID: 37611264
[TBL] [Abstract][Full Text] [Related]
24. No significant increase in Guillain-Barré syndrome after COVID-19 vaccination in adults: A vaccine adverse event reporting system study.
Jaffry M; Mostafa F; Mandava K; Rosario S; Jagarlamudi Y; Jaffry K; Kornitzer J; Jedidi K; Khan H; Souayah N
Vaccine; 2022 Sep; 40(40):5791-5797. PubMed ID: 36055875
[TBL] [Abstract][Full Text] [Related]
25. Real-world data on the incidence and risk of Guillain-Barré syndrome following SARS-CoV-2 vaccination: a prospective surveillance study.
Ha J; Park S; Kang H; Kyung T; Kim N; Kim DK; Kim H; Bae K; Song MC; Lee KJ; Lee E; Hwang BS; Youn J; Seok JM; Park K
Sci Rep; 2023 Mar; 13(1):3773. PubMed ID: 36882454
[TBL] [Abstract][Full Text] [Related]
26. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021.
Woo EJ; Mba-Jonas A; Dimova RB; Alimchandani M; Zinderman CE; Nair N
JAMA; 2021 Oct; 326(16):1606-1613. PubMed ID: 34617967
[TBL] [Abstract][Full Text] [Related]
27. Clinical characteristics and prognosis of temporary miller fisher syndrome following COVID-19 vaccination: a systematic review of case studies.
Alijanzadeh D; Soltani A; Afra F; Salmanpour F; Loghman AH; Samieefar N; Rezaei N
BMC Neurol; 2023 Sep; 23(1):332. PubMed ID: 37735648
[TBL] [Abstract][Full Text] [Related]
28. Associations of Guillain-Barré syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database.
Kim JE; Park J; Min YG; Hong YH; Song TJ
J Peripher Nerv Syst; 2022 Sep; 27(3):206-214. PubMed ID: 35751472
[TBL] [Abstract][Full Text] [Related]
29. Post COVID-19 vaccination Guillain-Barre syndrome: three cases.
Tabatabaee S; Rezania F; Alwedaie SMJ; Malekdar E; Badi Z; Tabatabaei SM; Mirzaasgari Z
Hum Vaccin Immunother; 2022 Nov; 18(5):2045153. PubMed ID: 35240922
[TBL] [Abstract][Full Text] [Related]
30. Guillain-Barre syndrome following COVID-19 vaccines: A review of literature.
Yu M; Nie S; Qiao Y; Ma Y
Front Immunol; 2023; 14():1078197. PubMed ID: 36875094
[TBL] [Abstract][Full Text] [Related]
31. Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine.
García-Grimshaw M; Michel-Chávez A; Vera-Zertuche JM; Galnares-Olalde JA; Hernández-Vanegas LE; Figueroa-Cucurachi M; Paredes-Ceballos O; Reyes-Terán G; Carbajal-Sandoval G; Ceballos-Liceaga SE; Arauz A; Valdés-Ferrer SI
Clin Immunol; 2021 Sep; 230():108818. PubMed ID: 34358692
[TBL] [Abstract][Full Text] [Related]
32. Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance.
Nasreen S; Calzavara A; Buchan SA; Thampi N; Johnson C; Wilson SE; Kwong JC;
Vaccine; 2022 May; 40(24):3305-3312. PubMed ID: 35527057
[TBL] [Abstract][Full Text] [Related]
33. Miller Fisher syndrome following COVID-19 vaccines: A scoping review.
Kim JE; Yoon BA; Kim YH; Kim JK; Bae JS
Acta Neurol Scand; 2022 Nov; 146(5):604-609. PubMed ID: 35938305
[TBL] [Abstract][Full Text] [Related]
34. Only blame SARS-CoV-2 vaccination for facial palsy after alternative etiologies have been ruled out.
Finsterer J; Scorza FA
Therapie; 2023; 78(4):463-464. PubMed ID: 37268504
[No Abstract] [Full Text] [Related]
35. Two possible etiologies of Guillain-Barré syndrome: mRNA-1273 (Moderna) vaccination and scrub typhus: A case report.
Hwang BW; Bong JB
Medicine (Baltimore); 2022 Dec; 101(48):e32140. PubMed ID: 36482517
[TBL] [Abstract][Full Text] [Related]
36. Association Between Guillain-Barré Syndrome and COVID-19 Infection and Vaccination: A Population-Based Nested Case-Control Study.
Bishara H; Arbel A; Barnett-Griness O; Bloch S; Cohen S; Najjar-Debbiny R; Gronich N; Auriel E; Saliba W
Neurology; 2023 Nov; 101(20):e2035-e2042. PubMed ID: 37852786
[TBL] [Abstract][Full Text] [Related]
37. A review of the potential neurological adverse events of COVID-19 vaccines.
Mohseni Afshar Z; Sharma A; Babazadeh A; Alizadeh-Khatir A; Sio TT; Taghizadeh Moghadam MA; Tavakolli Pirzaman A; Mojadad A; Hosseinzadeh R; Barary M; Ebrahimpour S
Acta Neurol Belg; 2023 Feb; 123(1):9-44. PubMed ID: 36385246
[TBL] [Abstract][Full Text] [Related]
38. Guillain-Barré syndrome in an era of global infections and 21st century vaccination.
Lunn MP
Curr Opin Neurol; 2022 Oct; 35(5):571-578. PubMed ID: 36069416
[TBL] [Abstract][Full Text] [Related]
39. Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?
Introna A; Caputo F; Santoro C; Guerra T; Ucci M; Mezzapesa DM; Trojano M
Clin Neurol Neurosurg; 2021 Sep; 208():106887. PubMed ID: 34418708
[TBL] [Abstract][Full Text] [Related]
40. Association of Guillain-Barré syndrome following COVID-19 vaccination.
Chowdhury S; Chowdhury S
Int J Immunopathol Pharmacol; 2023; 37():3946320231199349. PubMed ID: 37681361
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
